Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-26 @ 3:16 PM
NCT ID:
NCT07379203
Eligibility Criteria:
Inclusion Criteria:
Confirmed HIV infection CD4 count ≤100 cells/mm³ Expected to survive at least 48 hours CMV viral load \>500 international units (IU) / mL in blood. Provision of informed consent
Exclusion Criteria:
Confirmed or high level of clinical suspicion for CMV end organ disease as determined by the treating team CMV retinitis confirmed by retinal phography Pregnancy or breastfeeding Contraindication to valganciclovir (absolute neutrophil count \< 1.0 X109/L, haemoglobin \< 8 g/dL, platelets \< 100 X109/L) Allergy or prior adverse reaction to valganciclovir Expected to be unable to complete follow up Moribund - treating team considers patient is likely to die within next 48 hours Estimated creatinine clearance \< 40 mL/min ALT \> 3X ULN Receipt of high dose acyclovir as standard of care Unable to swallow whole tablets Concurrent administration of highly myelosuppressive drug, e.g. amphotericin B deoxycolate and linezolid
\-
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
15 Years
Study:
NCT07379203
Study Brief:
Protocol Section:
NCT07379203